34 completed, 3 unknown, 2 recruiting, 2 terminated. 18 Phase 3, 8 Phase 4, 4 Not applicable, 4 Phase 1, 4 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 18 | Completed 17, Terminated 1 |
| Phase 4 | 8 | Completed 7, Not yet recruiting 1 |
| Not applicable | 4 | Unknown 3, Recruiting 1 |
| Phase 1 | 4 | Completed 4 |
| Phase 2 | 4 | Completed 3, Terminated 1 |
Follow Erosive Esophagitis: new trials by email Literature Review of Erosive Esophagitis trials Research Report on Erosive Esophagitis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of the Safety of Vonoprazan Exposure in Pregnant Women and Their Offspring Vonoprazan - Erosive Esophagitis, Heartburn | Recruiting | Phathom Pharmaceuticals, Inc. | 728 | 2025-05-15 | 2026-09-18 | |
| Indonesian Study of Vonoprazan Vs Esomeprazole in Erosive Esophagitis Vonoprazan 20 mg, Esomeprazole - Erosive Esophagitis | Phase 4 | Not yet recruiting | Universitas Indonesia | 216 | 2024-12-09 | 2024-12-17 |
| A Study to Evaluate Vonoprazan Concentrations in Breast Milk of Healthy Lactating Women Receiving Vonoprazan 20 mg Once Daily or Vonoprazan 20 mg Twice Daily Vonoprazan - Erosive Esophagitis, Heartburn | Phase 1 | Completed | Phathom Pharmaceuticals, Inc. | 15 | 2024-05-07 | 2025-03-25 |
| A Study to Check the Safety of Dexlansoprazole and Learn If it Can Heal Erosive Esophagitis (EE) and Keep it Healed in Children 2 to 11 Years Old Dexlansoprazole - Erosive Esophagitis | Phase 2 | Terminated | Takeda | 24 | 2023-05-23 | 2026-05-06 |
| A Study to Evaluate the Long-Term Safety of BLI5100 in Patients With Gastroesophageal Reflux Disease BLI5100 - Non-erosive Reflux Disease, Erosive Esophagitis | Phase 3 | Completed | Braintree Laboratories | 400 | 2023-04-05 | 2025-09-26 |
| A Study to Evaluate the Efficacy and Safety of BLI5100 in Patients With Erosive Esophagitis BLI5100, PPI Control - Erosive Esophagitis | Phase 3 | Completed | Braintree Laboratories | 1250 | 2022-10-30 | 2026-06-16 |
| Endoscopic Evidence of Maintenance of Healing With Oral NEXIUM in Patients 1 to 11 Years Old With Erosive Esophagitis. Nexium 20mg, Nexium 10mg - Erosive Esophagitis | Phase 3 | Completed | AstraZeneca | 53 | 2022-07-01 | 2026-10-13 |
| JP-1366 20mg Versus Esomeprazole 40mg in Patients With Erosive Esophagitis JP-1366 20mg, Esomeprazole 40mg - Erosive Esophagitis | Phase 3 | Completed | Onconic Therapeutics Inc. | 300 | 2022-01-17 | 2024-08-27 |
| A Study in Patients With Erosive Esophagitis to Investigate Safety, Tolerability, and Healing Rates After 4 Weeks Treatment of X842 or Lansoprazole and Symptom Pattern During Subsequent 4 Weeks Treatment With Lansoprazole X842, X842 Dummy, Lansoprazole - Erosive Esophagitis | Phase 2 | Completed | Cinclus Pharma Holding AB | 248 | 2021-08-11 | 2026-07-01 |
| A Study to Evaluate the Safety, Tolerability and Pharmacokinetics/Pharmacodynamics of Oral Doses of H008 H008, H008 placebo, Lansoprazole - Erosive Esophagitis | Phase 1 | Completed | Jiangsu Carephar Pharmaceutical Co., Ltd. | 24 | 2021-06-24 | 2023-12-15 |
| Treatment Effect According to Timing of Administration of DWP14012 40 mg DWP14012 - Erosive Esophagitis | Not applicable | Unknown | Konkuk University Medical Center | 186 | 2021-02-01 | 2021-05-17 |
| Treatment Effect According to Timing of Administration of DWP14012 40 mg DWP14012 - Erosive Esophagitis | Not applicable | Unknown | Daewoong Pharmaceutical Co. LTD. | 186 | 2020-11-17 | 2020-11-03 |
| Real-life Study of Changes of Gastroesophageal Reflux Disease Manifestations Due to Behavioural and Diet Adherence diet adherence, No diet adherence, Change in physical activity - Gastroesophageal Reflux Disease, GERD | Not applicable | Recruiting | Federal State Budgetary Scientific Institution | 150 | 2020-01-31 | 2025-08-03 |
| Efficacy and Safety of Vonoprazan Compared to Lansoprazole in Participants With Erosive Esophagitis Vonoprazan, Lansoprazole - Erosive Esophagitis | Phase 3 | Completed | Phathom Pharmaceuticals, Inc. | 1027 | 2019-10-28 | 2022-07-29 |
| Clinical Trial to Assess the Efficacy and Safety of YYD601 in the Treatment of Esophageal Reflux Disease (ERD) YYD601 40mg, Nexium 40mg, Placebos - Erosive Esophagitis | Phase 3 | Completed | Yooyoung Pharmaceutical Co., Ltd. | 170 | 2019-01-29 | 2021-05-11 |
| Study to Evaluate the Efficacy and Safety of DWP14012 in Patients With Erosive Gastroesophageal Reflux Disease (Phase 3) DWP14012 40mg, DWP14012 40mg placebo, Esomeprazole 40mg - Erosive Esophagitis | Phase 3 | Completed | Daewoong Pharmaceutical Co. LTD. | 263 | 2018-12-13 | 2020-09-03 |
| Confocal Endomicroscopy for Permeability of Esophageal Wall in Refractory Gastroesophageal Reflux Disease (GERD) Confocal endomicroscopy, Endoscopic biopsies, Mucosal impedance (MI) - Gastro Esophageal Reflux, Barrett Esophagus | Not applicable | Unknown | McGuire Research Institute | 60 | 2017-04-28 | 2018-01-16 |
| Efficacy and Safety of Dexlansoprazole in Healing and Maintaining Healing of Erosive Esophagitis Dexlansoprazole, Lansoprazole, Placebo - Erosive Esophagitis | Phase 3 | Terminated | Takeda | 37 | 2016-12-21 | 2019-02-22 |
| Study to Confirm the Safety and Efficacy of CJ-12420 in Patients With Erosive Esophagitis CJ-12420 100mg QD, Esomeprazole 40mg, CJ-12420 50mg QD - Erosive Esophagitis | Phase 3 | Completed | HK inno.N Corporation | 302 | 2016-05-02 | 2017-09-12 |
| Vonoprazan Study in Patients With Erosive Esophagitis to Evaluate Long-term Safety Vonoprazan, Lansoprazole - Erosive Esophagitis | Phase 4 | Completed | Takeda | 208 | 2016-03-20 | 2023-12-13 |
Showing 20 of 42. Sign in to see all of them.
Gastroesophageal Reflux (13) · Heartburn (5) · Esophagitis, Peptic (3) · Barrett Esophagus (2) · Non-Erosive Reflux Disease (2) · Esophagitis (1)
Digestive System Diseases (15) · Esophageal Diseases (15) · Gastrointestinal Diseases (15) · Deglutition Disorders (14) · Esophageal Motility Disorders (14) · Pathological Conditions, Signs and Symptoms (5) · Signs and Symptoms (5) · Signs and Symptoms, Digestive (5) · Gastroenteritis (4) · Duodenal Diseases (3) · Esophagitis (3) · Intestinal Diseases (3) · Peptic Ulcer (3) · Stomach Diseases (3) · Neoplasms (2)
Esomeprazole (13) · Lansoprazole (12) · 1-(5-(2-fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl)-N-methylmethanamine (11) · Dexlansoprazole (4) · fexuprazan (3) · 1-(5-(1H-indol-5-yl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl)-N-methylmethanamine (1) · Dosage Forms (1) · Endoscopic Mucosal Resection (1) · Exercise (1) · Famotidine (1) · Omeprazole (1) · ilaprazole (1) · lafutidine (1) · omeprazole, sodium bicarbonate drug combination (1) · tegoprazan (1)
Takeda (11) · AstraZeneca (5) · HK inno.N Corporation (4) · Phathom Pharmaceuticals, Inc. (3) · Braintree Laboratories (2) · Daewoong Pharmaceutical Co. LTD. (2) · Mayo Clinic (2) · Boryung Pharmaceutical Co., Ltd (1) · Chang Gung Memorial Hospital (1) · Cinclus Pharma Holding AB (1) · Federal State Budgetary Scientific Institution (1) · Il-Yang Pharm. Co., Ltd. (1) · Jiangsu Carephar Pharmaceutical Co., Ltd. (1) · Konkuk University Medical Center (1) · McGuire Research Institute (1)
United States (18) · South Korea (12) · Japan (5) · Poland (4) · Belgium (3) · China (3) · Hungary (3) · Italy (3) · Taiwan (3) · Bulgaria (2) · Czechia (2) · Malaysia (2) · Mexico (2) · Portugal (2) · Argentina (1)
Paula Fernstrom (2) · Ari F Syam, MD (1) · Hyun Chae Jung, Ph.D (1) · Hyun-Chae Jung, MD, PhD (1) · Jeffrey Alexander, MD (1) · Kim JinHo (1) · Leah Hollins (1) · Min-Gul Kim, MD (1)
PMID 17305763, PMID 18493207, PMID 20540767, PMID 20626453, PMID 20706150, PMID 22415199, PMID 25245625, PMID 26121347, PMID 26121348, PMID 26422095, PMID 26422096, PMID 31409606, PMID 36228734, PMID 38654422, PMID 38976448, PMID 39209187, PMID 40183130, PMID 40470733, PMID 8898633
2019 (1), 2023 (1), R01AR057102 (1)